Stock Analysis, Dividends, Split History

SNSS / Sunesis Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)75.53
Enterprise Value ($M)57.41
Book Value ($M)9.97
Book Value / Share0.28
Price / Book7.46
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 34,291,000
Common Shares Outstanding 34,348,917
Preferred Stock Shares Outstanding 17,697
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.65
Return on Assets (ROA)-0.82
Return on Equity (ROE)-1.69
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.82
Income Statement (mra) ($M)
Revenue Participation Right Payment Rate0.07
License And Other Revenue669,000.00
Operating Income-34.42
Net Income-35.46
Earnings Per Share Diluted-1.45
Earnings Per Share Basic-1.45
Cash Flow Statement (mra) ($M)
Cash From Operations-36.14
Cash from Investing29.75
Cash from Financing-36.14
Identifiers and Descriptors
Central Index Key (CIK)1061027
Related CUSIPS
867328901 867328900 867328951 867328950 867328700

Split History

Stock splits are used by Sunesis Pharmaceuticals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="

Related News Stories

ArQule: Continued Upside As Additional Catalysts Loom

2018-07-08 seekingalpha
AKT inhibitor miransertib in certain oncology and rare disease indications will increasingly garner attention in the second half of the year. (5-1)

Sunesis Pharmaceuticals: A Run-Up Interrupted Set To Resume?

2018-06-27 seekingalpha
The growing gap in valuation is intriguing, and an update on the clinical progress of SNS-062 in fall represents a near-term catalyst. (46-4)

Institutional Top Ideas Series: Biotechnology Value Fund

2018-06-04 seekingalpha
BVF returns have really ramped up recently, made more impressive by their lower turnover compared to other funds we´ve looked at. (147-3)

Sunesis Pharmaceuticals' (SNSS) Management on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good day, ladies and gentlemen and welcome to Sunesis Pharmaceuticals First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. (15-0)

Otonomy (OTIC) Sees Hammer Chart Pattern: Time to Buy?

2018-04-09 zacks
Otonomy, Inc. (OTIC - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because OTIC recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. (112-0)

Silicon Investor Message Boards

This table lists all message boards related to SNSS / Sunesis Pharmaceuticals, Inc. on message board site Silicon Investor.

Sunesis Pharmaceuticals (SNSS) Sunesis Pharmaceuticals (SNSS) Sunesis Pharmaceuticals (SNSS)
CUSIP: 867328601